5 results match your criteria: "National Hospital Hipolito Unanue[Affiliation]"
Successful Evolution of Atrial Septal Defect Closure in an Elderly Patient With Complex Cardiovascular Disease.
CASE (Phila)
August 2024
Department of Nuclear Cardiology, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
• ASD closure in elderly patients improves RV remodeling. • ASD closure is feasible in older patients with arrhythmias and pulmonary hypertension. • Clinical and hemodynamic status is improved after ASD closure.
View Article and Find Full Text PDFOzaki Procedure Plus Aortic Annular Enlargement in an Extremely Narrow Aortic Annulus: A Surgical Challenge.
Innovations (Phila)
November 2023
MINSA, National Hospital Hipolito Unanue, Cardiovascular Surgery Department, Lima, Peru.
Article Synopsis
- A 19-year-old woman with a past aortic valve balloon procedure was admitted due to severe aortic valve stenosis and a narrow annulus.
- The surgical team initially planned to reconstruct the aortic valve using her own pericardium.
- During surgery, they discovered a unicuspid valve and proceeded to enlarge the aortic valve annulus.
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J
June 2016
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.
View Article and Find Full Text PDFEffectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J
April 2016
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.
View Article and Find Full Text PDF